RxDoctor Payments Data

Perwaiz Meraj, MD

Interventional Cardiology · Manhasset, NYNPI 1104088962

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (57.8%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 27 manufacturers reported payments, led by Abiomed at 37.4% of the total.

$73,941in general payments, 2019–2025

Across 195 payments — averaging $379.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abiomed$28K
  • Magenta Medical Inc$14K
  • Cardiovascular Systems Inc.$10K
  • Medtronic$6K
  • Biotronik Inc.$5K
  • Spectrawave, Inc$3K
  • plus $9K from 21 others
$123,693in research payments, 2019–2025

Across 34 payments — averaging $3638.01 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Abbott$69K
  • Magenta Medical Inc$42K
  • Bayer$12K

What the payments were for

  • Consulting fees$18,75025%
  • Speaking & faculty fees$42,71758%
  • Travel & lodging$4,7606%
  • Food & beverage$7,71310%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$73,941 in reported general payments places this provider in the 85th percentile of 382 interventional cardiology providers in New York.

See all interventional cardiology providers in New York

Medicare billing

Part B allowed, 2024
$141,640
Medicare patients
687
Services billed
1,387

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan18$29,476
EliquisApixaban21$18,154
ClopidogrelClopidogrel Bisulfate94$1,097
Atorvastatin Calcium108$1,060
Carvedilol113$953
Metoprolol Succinate37$436
Chlorthalidone18$430
Valsartan24$362
Rosuvastatin Calcium29$337
Lisinopril52$323
Pantoprazole Sodium17$308
Losartan Potassium31$297
Omeprazole11$143
Furosemide16$123
Amlodipine Besylate22$102

Paid to pharmacies, not to this prescriber.

Other interventional cardiology in Manhasset

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →